Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 315 Lymphoma 282 Leukemia 227 Precursor Cell Lymphoblastic Leukemia-Lymphoma 216 Lymphoma, Non-Hodgkin 178 Leukemia, Lymphocytic, Chronic, B-Cell 177 Multiple Myeloma 174 Lymphoma, Large B-Cell, Diffuse 174 Lymphoma, Follicular 142 Leukemia, Myeloid, Acute 136 Lymphoma, Mantle-Cell 126 Hodgkin Disease 125 Burkitt Lymphoma 118 Myelodysplastic Syndromes 110 Lymphoma, Large-Cell, Immunoblastic 89 Lymphoma, B-Cell, Marginal Zone 85 Recurrence 67 Neoplasms, Plasma Cell 62 Leukemia, Myeloid, Chronic-Phase 59 Neuroblastoma 56 Dendritic Cell Sarcoma, Interdigitating 56 Leukemia, Myeloid, Accelerated Phase 55 Myeloproliferative Disorders 54 Melanoma 54 Congenital Abnormalities 48 Neoplasms 47 Leukemia, Myelomonocytic, Chronic 45 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 45 Blast Crisis 45 Lymphoma, Large-Cell, Anaplastic 44

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Survival Without Progression × Cyclophosphamide × Clear all

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡